Novo Nordisk shifts US media business from WPP to Omnicom

Source: www.unsplash.com

The appointment covers media planning and buying in the US for Novo Nordisk, whose portfolio includes blockbuster diabetes and weight-loss brands Ozempic and Wegovy. The account is understood to be one of the year's most closely watched media pitches, given the rapid growth of the GLP-1 market and Novo Nordisk's sizeable advertising investment.

The move represents another setback for WPP, which has been under pressure amid a series of account reviews and client changes globally. Novo Nordisk's decision follows a competitive process that saw Omnicom emerge as the successful bidder for the US business.

WPP results beat analyst forecasts, sees shares jump up

6 Aug 2026